Nature Biotechnology 2004 Sabine Louet - Abstracts
| Nature Biotechnology 2004 Sabine Louet | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| Can China bring its own pipeline to the market? | Business | Sabine Louet | |||
| EU enlargement brings biotech opportunities. | Business | Sabine Louet | |||
| E&Y report backs Asia-Pacific biotech. | Business | Sabine Louet | |||
| France critiques its incubators before refinancing. | Business | Sabine Louet | |||
| India aims to become the main bioinformatics hub. | Business | Sabine Louet, K. S. Jayaraman | |||
| IPO floodgates unlikely to open after Ark floatation.(initial public offering) | Business | Sabine Louet | |||
| Ireland launches regenerative medicine research center. | Business | Sabine Louet | |||
| Japanese firms broaden investment focus to early biotech. | Business | Sabine Louet, Doug Sipp | |||
| New EU antitrust law burdens licensing.(European Union) | Business | Sabine Louet | |||
| Reagent safety issues surface for cell/tissue therapies. | Business | Sabine Louet | |||
| UK to pursue contract clinical trials. | Business | Sabine Louet | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.